{"id":"W2104721463","doi":"10.1158/1078-0432.ccr-07-0382","title":"Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Sorafenib; Medicine; Erlotinib; Pharmacokinetics; Adverse effect; Rash; Pharmacology; Internal medicine; Oncology; Hepatocellular carcinoma; Epidermal growth factor receptor; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001671816,0.0001049945,0.000520359,0.0001794476,0.00006750106,0.00000665575,0.00005879108,0.00007192699,0.00005091138],"category_scores_gemma":[0.0006882228,0.00007386591,0.00004959794,0.0004559752,0.0004100626,0.00005738835,0.00006118488,0.000390772,0.000001463381],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001561021,"about_ca_system_score_gemma":0.0002399322,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001981614,"about_ca_topic_score_gemma":0.0004782355,"domain_scores_codex":[0.9980108,0.0001164283,0.000605637,0.0003150476,0.0006073386,0.0003447567],"domain_scores_gemma":[0.9984878,0.0005569779,0.0001128079,0.0001642504,0.00052265,0.0001555145],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3913499,0.007021348,0.4142135,0.00006754646,0.0001040267,0.00002941625,0.0002791912,9.529037e-7,0.00006703882,0.00004554104,0.0001504484,0.1866712],"study_design_scores_gemma":[0.2627233,0.03092451,0.7049245,0.0001645616,0.00002605733,2.502473e-7,0.0001418269,0.00001409403,0.0005982029,0.00007602714,0.0003311047,0.00007559051],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966182,0.0004584855,0.000004052783,0.000351858,0.0001308563,0.001682891,0.00002011762,0.00001099063,0.0007225989],"genre_scores_gemma":[0.9992259,0.0003020619,0.00007899792,0.00004360186,0.00008331714,0.00009356599,0.00002232018,0.00001454037,0.0001357114],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.290711,"threshold_uncertainty_score":0.3012164,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1143076126728617,"score_gpt":0.5290445278227675,"score_spread":0.4147369151499057,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}